NCT05425992 Improving Communication and Building a Stronger Medical Home Among Spanish-speaking Families
| NCT ID | NCT05425992 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Colorado, Denver |
| Condition | Leukemia |
| Study Type | OBSERVATIONAL |
| Enrollment | 20 participants |
| Start Date | 2022-03-17 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 20 participants in total. It began in 2022-03-17 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will seek to improve communication with Spanish speaking families and patients with Cancer and Blood Disorders.
Eligibility Criteria
Inclusion Criteria: * 0 to 22 years of age * Diagnosis of leukemia or non-Hodgkin lymphoma * Spanish as preferred language for patient, parent or guardian * Received or receiving care at the Center for Cancer and Blood Disorders (CCBD) Exclusion Criteria: * Patients without oncologic diagnosis * Patients with parents whose language preference is English * Patients who received care solely outside of the CCBD
Contact & Investigator
Ashley Rogers
PRINCIPAL INVESTIGATOR
Children's Hospital Colorado
Frequently Asked Questions
Who can join the NCT05425992 clinical trial?
This trial is open to participants of all sexes, up to 22 Years, studying Leukemia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05425992 currently recruiting?
Yes, NCT05425992 is actively recruiting participants. Contact the research team at wendy.moore@childrenscolorado.org for enrollment information.
Where is the NCT05425992 trial being conducted?
This trial is being conducted at Aurora, United States.
Who is sponsoring the NCT05425992 clinical trial?
NCT05425992 is sponsored by University of Colorado, Denver. The principal investigator is Ashley Rogers at Children's Hospital Colorado. The trial plans to enroll 20 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.